- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
J Infect Dev Ctries. 2019 Nov 30;13(11):1062-1067. doi: 10.3855/jidc.11447.
Mutations in reverse transcriptase region of HBV affect Hepatitis B surface antigen titers and its correlation with HBV DNA.
Shen H1, Chen C2, Ye C3, Zhang H4, Hang S5, Chen M6, Zhu Z7, Xue Y8, Liu L9.
Author information
1
Department of Clinical Laboratory, the Third peoples' Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
2
Department of Clinical Laboratory, the Third peoples' Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
3
Institute of Hepatology, the Third People's Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
4
Department of Clinical Laboratory, the Third peoples' Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
5
Department of Clinical Laboratory, the Third peoples' Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
6
Department of Clinical Laboratory, the Third peoples' Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
7
Department of Clinical Laboratory, the Third peoples' Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
8
Institute of Hepatology, the Third People's Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
9
Institute of Hepatology, the Third People's Hospital of Changzhou, Changzhou, Jiangsu, China. [email protected].
Abstract
INTRODUCTION:
The impact of mutations in the reverse transcriptase region of HBV on serum HBsAg titer and its correlation with HBV DNA is largely unknown.
METHODOLOGY:
A total of 644 patients, with a history of lamivudine or adefovir dipivoxil resistance who underwent genotypic resistance tests, were enrolled in this study. Serum HBsAg, hepatitis B e antigen and HBV DNA were quantified, and the HBV RT region was sequenced and analyzed. Then, the patients were divided into five sub-groups, including M204I/V, L180M+M204I/V, A181T/V, N236T and A181T/V+N236T according to the mutation spectra.
RESULTS:
HBsAg was lower in the wild-type and A181T/V+N236T groups as compared to the M204I/V, L180M+M204I/V and N236T groups. HBsAg was positively correlated with HBV DNA levels in the wild-type group (r = 0.322, p < 0.01), as well as in the M204I/V, L180M+M204I/V, A181T/V, and N236T subgroups, while no correlation was found in the A181T/V+N236T subgroup (r = 0.159, p = 0.217). Moreover, for patients with N236T mutation, HBsAg was positively correlated with HBV DNA level in the HBeAg negative group (r = 0.435, p = 0.016), but not in the HBeAg positive group (r = 0.105, p = 0.594). For patients with A181T/V or N236T mutation, HBsAg was positively correlated with HBV DNA in older patients (≥ 40 years), but not in younger patients (< 40 years).
CONCLUSIONS:
Serum HBsAg titer and its correlation with HBV DNA may be affected by mutations in the reverse transcriptase region of HBV, that should be re-evaluated in patients with antiviral resistance.
Copyright (c) 2019 Longgen Liu, hongyu shen, chunhua chen, chunyan ye, hongyu zhang, shuangxiong hang, min chen, zhen zhu, yuan xue.
KEYWORDS:
drug resistance; hepatitis B surface antigen; hepatitis B virus; mutation
PMID:
32087080
DOI:
10.3855/jidc.11447 |
|